Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer

Cancer Gene Therapy volume 18, pages 167–175 (2011)Cite this article

Subjects

Abstract

In 2005, we initiated a clinical trial that examined the efficacy of the oncolytic virus HF10 to treat pancreatic cancer. Pancreatic cancer continues to have a high mortality rate, despite multimodal treatments for patients, and new therapeutic methods are greatly needed. The current mainstream methods for cancer treatment include biological therapeutics such as trastuzumab (Herceptin) for breast cancer or erlotinib (Tarceva) for non-small cell lung cancer. Oncolytic virus therapy is a new and promising treatment strategy for cancer. Oncolytic viruses are novel biological therapeutics for advanced cancer that appear to have a wide spectrum of anticancer activity with minimal human toxicity. To examine the efficacy of oncolytic virus therapy for pancreatic cancer, we initiated pilot studies by injecting six patients with non-resectable pancreatic cancer with three doses of HF10. All patients were monitored for 30 days for local and systemic adverse effects and were not administered any other therapeutics during this period. There were no adverse side-effects, and we observed some therapeutic potential based on tumor marker levels, survival, pathological findings and diagnostic radiography. The tumors were classified as stable disease in three patients, partial response in one patient and progressive disease in two patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867–874.

    Article  CAS  PubMed  Google Scholar 

  2. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17: 199–207.

    Article  CAS  PubMed  Google Scholar 

  3. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9: 398–406.

    Article  CAS  PubMed  Google Scholar 

  4. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004; 11: 1648–1658.

    Article  CAS  PubMed  Google Scholar 

  5. Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006; 17: 1214–1224.

    Article  CAS  PubMed  Google Scholar 

  6. Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009; 17: 389–394.

    Article  CAS  PubMed  Google Scholar 

  7. Takakuwa H, Goshima F, Nozawa N, Yoshikawa T, Kimata H, Nakao A et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003; 148: 813–825.

    Article  CAS  PubMed  Google Scholar 

  8. Kimata H, Takakuwa H, Goshima F, Teshigahara O, Nakao A, Kurata T et al. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatogastroenterology 2003; 50: 961–966.

    PubMed  Google Scholar 

  9. Seino T, Nakadaira H, Endoh K, Yamamoto M . Changes in pancreatic cancer mortality, period patterns, and birth cohort patterns in Japan: analysis of mortality data in the period 1968–2002. Environ Health Prev Med 2008; 13: 234–242.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S, Nakashima T et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 2006; 126: 1115–1117.

    Article  PubMed  Google Scholar 

  11. Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T et al. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 2004; 15: 988–989.

    Article  CAS  PubMed  Google Scholar 

  12. Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, Goshima F et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 2006; 13: 1078–1084.

    Article  PubMed  Google Scholar 

  13. Nakao A, Takeda S, Shimoyama S, Kasuya H, Kimata H, Teshigahara O et al. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Curr Cancer Drug Targets 2007; 7: 169–174.

    Article  CAS  PubMed  Google Scholar 

  14. Nomura N, Kasuya H, Watanabe I, Shikano T, Shirota T, Misawa M et al. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Cancer Chemother Pharmacol 2009; 63: 321–330.

    Article  PubMed  Google Scholar 

  15. Choi H . Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005; 7: 307–311.

    Article  PubMed  Google Scholar 

  16. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751–8757.

    CAS  PubMed  Google Scholar 

  17. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ . Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656–4662.

    CAS  PubMed  Google Scholar 

  18. Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–1334.

    Article  CAS  PubMed  Google Scholar 

  19. Kasuya H, Pawlik TM, Mullen JT, Donahue JM, Nakamura H, Chandrasekhar S et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 2004; 64: 2561–2567.

    Article  CAS  PubMed  Google Scholar 

  20. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10: 2741–2755.

    Article  CAS  PubMed  Google Scholar 

  21. Miller CG, Fraser NW . Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther 2003; 7: 741–747.

    Article  CAS  PubMed  Google Scholar 

  22. Thomas DL, Fraser NW . HSV-1 therapy of primary tumors reduces the number of metastases in an immnuno-competent model of metastatic breast cancer. Mol Ther 2003; 8: 543–551.

    Article  CAS  PubMed  Google Scholar 

  23. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL . Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–943.

    Article  CAS  PubMed  Google Scholar 

  24. Watanabe I, Kasuya H, Nomura N, Shikano T, Shirota T, Kanazumi N et al. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol 2008; 61: 875–882.

    Article  CAS  PubMed  Google Scholar 

  25. Tysome JR, Lemoine NR, Wang Y . Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes. Curr Opin Mol Ther 2009; 11: 664–669.

    CAS  PubMed  Google Scholar 

  26. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, Andrea McCart J . Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18: 251–263.

    Article  CAS  PubMed  Google Scholar 

  27. Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F ; et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther 2007; 14: 918–926.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The Takeda Science Foundation 2008 Grant-Aid for Scientific Research in Japan.

Author information

Authors and Affiliations

  1. Department of Surgery II, Nagoya University Graduate School of Medicine, Nagoya, Japan

    A Nakao, H Kasuya, T T Sahin, N Nomura, A Kanzaki, M Misawa, T Shirota, S Yamada, T Fujii, H Sugimoto, T Shikano, S Nomoto, S Takeda & Y Kodera

  2. Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Y Nishiyama

Authors
  1. A Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Kasuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T T Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Kanzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Misawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Shirota
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Shikano
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Nomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Y Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Y Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Nakao.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakao, A., Kasuya, H., Sahin, T. et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther 18, 167–175 (2011). https://doi.org/10.1038/cgt.2010.65

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2010.65

Keywords

This article is cited by

Search

Advanced search

Quick links